Menopause News and Research

RSS

Menopause is the time in a woman's life when her period stops. It usually occurs naturally, most often after age 45. Menopause happens because the woman's ovary stops producing the hormones estrogen and progesterone.

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

Blood test to help predict when women will hit menopause

Researchers have developed a way of accurately predicting when women will hit the menopause using a simple blood test. The average difference between the predicted age and the actual age that the women in their study reached the menopause was only a third of a year, and the maximum margin of error was between three and four years.

28 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

Better test to predict menopause on the horizon

With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.

28 Jun 2010

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Researchers at UT Southwestern Medical Center have pinpointed a set of biological mechanisms through which estrogen confers its beneficial effects on the cardiovascular system, independent of the hormone's actions on cancer. Their investigation suggests that drugs targeting a specific subpopulation of estrogen receptors found outside the cell nucleus might activate the cardiovascular benefits of estrogen without increasing cancer risk.

24 Jun 2010

BioSante closes $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

24 Jun 2010

Endocrine Society presents Scientific Statement on menopausal hormone therapy at ENDO 2010

The Endocrine Society presented its Scientific Statement on menopausal hormone therapy Monday in San Diego, Calif. at ENDO 2010: The 92nd Annual Meeting & Expo.

23 Jun 2010

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

Women who experience early menopause may have cardiovascular disease later in life: Study

Women who experience early menopause appear to have more than twice the risk of having a heart attack, stroke or other cardiovascular disease event later in life than do women who do not go through early menopause, a new study indicates. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Scientists identify symptoms associated with late-onset hypogonadism

Scientists have for the first time identified the symptoms associated with what has been termed late-onset hypogonadism or 'male menopause' caused by a reduction in testosterone production in ageing men.

17 Jun 2010

Study results of genes regulated by ERB published in Journal of Biological Chemistry

Bionovo Inc. today announced the publication of results from a study demonstrating the three distinct classes of genes regulated by estrogen receptor beta. The results are published in the Journal of Biological Chemistry. This is an important discovery for future development of selective drugs regulating this pathway.

11 Jun 2010

2010 GAPS sheds light on the painful reality of what life is like for gout patients

The 2010 Gout Attitudes Patient Survey, a new study of Americans with gout, released by Men's Health Network, sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent feel as though others do not take the condition seriously.

11 Jun 2010

Therapies for female sexual dysfunction

Many women experience problems in the bedroom at one time or another. Female sexual dysfunction is not uncommon and although some women and healthcare providers have difficulty discussing it, it has been recognized by the medical community for decades. In fact, for the last twenty years, it has been listed in the Diagnostic and Statistical Manual of Mental Disorders, a manual published by the American Psychiatric Association, used to classify and diagnose psychological disorders.

10 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

HRT patches containing low doses of oestrogen carry less risk of stroke than oral therapy: Study

Hormone replacement therapy skin patches containing low doses of oestrogen carry less risk of stroke than oral therapy and may represent a safer alternative to tablets, suggests a study published on bmj.com today.

4 Jun 2010

Researchers identify new therapeutic target for cognitive decline

Researchers at Mount Sinai School of Medicine have found that certain types of specializations on nerve cells called "spines" are depleted as a person ages, causing cognitive decline in the part of the brain that mediates the highest levels of learning.

3 Jun 2010